Cell And Gene Therapy Companies Fear More Market Delays From EU’s Single Review Plans

Regulations Aimed At Streamlining Could Make Things Worse

Biopharma fears that the Joint Clinical Assessment, a first step to harmonizing health technology assessments in the EU, is not fit for purpose for cell and gene therapies and will increase rather than eliminate market access delays.

Zolgensma Glove

Plans to streamline the route to market for new cell and gene therapies across the European Union are raising concerns that they could make actually matters worse, particularly for small-to-medium cell and gene therapy companies who fear they will be hit first, and hardest.

Most new medicines launched in the EU’s 27 member states are approved via the central European Medicines Agency (EMA), and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip